Biocept to Participate in Two July Investment Conferences

Rhea-AI Summary

Biocept, Inc (Nasdaq: BIOC) announces that President and CEO Michael Nall will attend two upcoming investment conferences. The first is the Brookline Capital Markets Newport Symposium on July 26, focusing on transformative biotech, featuring group discussions and one-on-one meetings. The second is the A.G.P.’s Virtual MedTech Summer Conference on July 29, also including one-on-one investor meetings. Biocept specializes in molecular diagnostic assays aimed at enhancing cancer treatment and monitoring.

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will participate at the following investment conferences:

• Brookline Capital Markets Newport Symposium, “Transformative Biotech – Cancer, Rare Diseases, and Viruses,” which will feature group and one-on-one investor meetings and panel discussions with scientific and industry experts. The conference is being held in Newport, R.I. on July 26.

• A.G.P.’s Virtual MedTech Summer Conference, which will feature one-on-one investor meetings. The conference is being held on July 29.

The Biocept Investor Presentation is available here.

About Biocept

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its broad portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide™ cerebrospinal fluid (CSF) assay that detects cancer that has metastasized to the central nervous system. Biocept’s patented Target Selector™ technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. Biocept also is leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210719005137/en/

FAQ

What conferences is Biocept attending in July 2021?

Biocept is attending the Brookline Capital Markets Newport Symposium on July 26 and A.G.P.’s Virtual MedTech Summer Conference on July 29.

Who is representing Biocept at the investment conferences?

Michael Nall, President and CEO of Biocept, will represent the company.

What is the focus of the Brookline Capital Markets Newport Symposium?

The focus is on transformative biotech, including discussions on cancer, rare diseases, and viruses.

When is Biocept's investor presentation available?

The Biocept investor presentation is available online as noted in their press release.

What technology does Biocept use for cancer diagnostics?

Biocept uses patented Target Selector™ technology for analyzing cancer-related molecular markers.